文献

J-GLOBAL ID：201602220804103301   整理番号：16A0711756

急性非代償性心不全患者におけるトルバプタン治療に対する反応者の臨床的特徴:保存された腎臓の大きさの重要性

Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size

著者 (21件)： Toda Hironobu (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Toda Hironobu (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Nakamura Kazufumi (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Nakahama Makoto (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Wada Tadashi (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Wada Tadashi (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Watanabe Atsuyuki (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Watanabe Atsuyuki (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Hashimoto Katsushi (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Hashimoto Katsushi (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Terasaka Ritsuko (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Tokioka Koji (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Nishii Nobuhiro (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Miyoshi Toru (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Kohno Kunihisa (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Kawai Yusuke (Department of Cardiology, Ehime Prefectural Central Hospital, Ehime, Japan) ,  Miyaji Kohei (Department of Clinical Science, National Hospital Organization Okayama Medical Center, Okayama, Japan) ,  Koide Yuji (Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa, Japan) ,  Tachibana Motomi (Department of Cardiology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan) ,  Yoshioka Ryo (Department of Cardiology, Sakakibara Heart Institute of Okayama, Okayama, Japan) ,  Ito Hiroshi (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan)
資料名： Journal of Cardiology  (Journal of Cardiology)
巻： 67  号： 2  ページ： 177-183  発行年： 2016年02月 
JST資料番号： W2218A  ISSN： 0914-5087  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： イギリス (GBR)  言語： 英語 (EN)

抄録/ポイント： 背景:最近の臨床試験は,心不全患者における,経口バソプレシン...

シソーラス用語： *心不全 ,...
準シソーラス用語： *急性非代償性心不全 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A0711756&from=J-GLOBAL&jstjournalNo=W2218A") }}

著者キーワード (3件)： Heart failure ,  Vasopressin ,  Kidney size

分類 (3件)： 泌尿生殖器疾患の薬物療法  (GM05020V) ,  泌尿器作用薬の臨床への応用  (GW11020C) ,  泌尿生殖器の診断  (GM02000E)

物質索引 (1件)： トルバプタン

引用文献 (22件)：

• JCS-Joint-Working-Group. Guidelines for treatment of acute heart failure (JCS 2011). Circ J 2013;77:2157-201.
• Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-6.
• Gheorghiade M, Konstam MA, Burnett Jr JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. J Am Med Assoc 2007;297:1332-43.
• Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011;25(Suppl. 1):S57-65.
• Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, Sugiura E, Kumagai N, Nakamori S, Nakajima H, Hoshino K, Machida H, Okamoto S, Onishi K, Nakamura M, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012;60:462-9.

タイトルに関連する用語 (9件)： 急性非代償性心不全 ,  患者 ,  トルバプタン ,  治療 ,  臨床 ,  保存 ,  腎臓 ,  大きさ ,  重要性